These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

576 related items for PubMed ID: 19454302

  • 1. Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine.
    Pandi-Perumal SR, Moscovitch A, Srinivasan V, Spence DW, Cardinali DP, Brown GM.
    Prog Neurobiol; 2009 Aug; 88(4):264-71. PubMed ID: 19454302
    [Abstract] [Full Text] [Related]

  • 2. Circadian rhythm in bipolar disorder: A review of the literature.
    Takaesu Y.
    Psychiatry Clin Neurosci; 2018 Sep; 72(9):673-682. PubMed ID: 29869403
    [Abstract] [Full Text] [Related]

  • 3. Circadian rhythms, melatonin and depression.
    Quera Salva MA, Hartley S, Barbot F, Alvarez JC, Lofaso F, Guilleminault C.
    Curr Pharm Des; 2011 Sep; 17(15):1459-70. PubMed ID: 21476953
    [Abstract] [Full Text] [Related]

  • 4. Pathophysiology of depression: role of sleep and the melatonergic system.
    Srinivasan V, Pandi-Perumal SR, Trakht I, Spence DW, Hardeland R, Poeggeler B, Cardinali DP.
    Psychiatry Res; 2009 Feb 28; 165(3):201-14. PubMed ID: 19181389
    [Abstract] [Full Text] [Related]

  • 5. Addressing circadian rhythm disturbances in depressed patients.
    Lam RW.
    J Psychopharmacol; 2008 Sep 28; 22(7 Suppl):13-8. PubMed ID: 18753278
    [Abstract] [Full Text] [Related]

  • 6. Role of melatonin in mood disorders and the antidepressant effects of agomelatine.
    Srinivasan V, De Berardis D, Shillcutt SD, Brzezinski A.
    Expert Opin Investig Drugs; 2012 Oct 28; 21(10):1503-22. PubMed ID: 22876742
    [Abstract] [Full Text] [Related]

  • 7. [Depression as chronobiological illness].
    Kálmán J, Kálmán S.
    Neuropsychopharmacol Hung; 2009 Jun 28; 11(2):69-81. PubMed ID: 19827314
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Chronic agomelatine treatment corrects the abnormalities in the circadian rhythm of motor activity and sleep/wake cycle induced by prenatal restraint stress in adult rats.
    Mairesse J, Silletti V, Laloux C, Zuena AR, Giovine A, Consolazione M, van Camp G, Malagodi M, Gaetani S, Cianci S, Catalani A, Mennuni G, Mazzetta A, van Reeth O, Gabriel C, Mocaër E, Nicoletti F, Morley-Fletcher S, Maccari S.
    Int J Neuropsychopharmacol; 2013 Mar 28; 16(2):323-38. PubMed ID: 22310059
    [Abstract] [Full Text] [Related]

  • 10. Melatonergic drugs in clinical practice.
    Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, Cardinali DP.
    Arzneimittelforschung; 2008 Mar 28; 58(1):1-10. PubMed ID: 18368944
    [Abstract] [Full Text] [Related]

  • 11. Agomelatine: innovative pharmacological approach in depression.
    Popoli M.
    CNS Drugs; 2009 Mar 28; 23 Suppl 2():27-34. PubMed ID: 19708723
    [Abstract] [Full Text] [Related]

  • 12. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients.
    Quera-Salva MA, Lemoine P, Guilleminault C.
    Hum Psychopharmacol; 2010 Apr 28; 25(3):222-9. PubMed ID: 20373473
    [Abstract] [Full Text] [Related]

  • 13. Agomelatine as chronopsychopharmaceutics restoring circadian rhythms and enhancing resilience to stress: a wishfull thinking or an innovative strategy for superior management of depression?
    Jakovljević M.
    Psychiatr Danub; 2011 Mar 28; 23(1):2-9. PubMed ID: 21448091
    [Abstract] [Full Text] [Related]

  • 14. The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice.
    De Berardis D, Marini S, Fornaro M, Srinivasan V, Iasevoli F, Tomasetti C, Valchera A, Perna G, Quera-Salva MA, Martinotti G, di Giannantonio M.
    Int J Mol Sci; 2013 Jun 13; 14(6):12458-83. PubMed ID: 23765220
    [Abstract] [Full Text] [Related]

  • 15. Hypnotic and Melatonin/Melatonin-Receptor Agonist Treatment in Bipolar Disorder: A Systematic Review and Meta-Analysis.
    McGowan NM, Kim DS, de Andres Crespo M, Bisdounis L, Kyle SD, Saunders KEA.
    CNS Drugs; 2022 Apr 13; 36(4):345-363. PubMed ID: 35305257
    [Abstract] [Full Text] [Related]

  • 16. Melatonin and melatonergic drugs on sleep: possible mechanisms of action.
    Srinivasan V, Pandi-Perumal SR, Trahkt I, Spence DW, Poeggeler B, Hardeland R, Cardinali DP.
    Int J Neurosci; 2009 Apr 13; 119(6):821-46. PubMed ID: 19326288
    [Abstract] [Full Text] [Related]

  • 17. The preclinical discovery and development of agomelatine for the treatment of depression.
    Konstantakopoulos G, Dimitrakopoulos S, Michalopoulou PG.
    Expert Opin Drug Discov; 2020 Oct 13; 15(10):1121-1132. PubMed ID: 32568567
    [Abstract] [Full Text] [Related]

  • 18. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
    San L, Arranz B.
    Eur Psychiatry; 2008 Sep 13; 23(6):396-402. PubMed ID: 18583104
    [Abstract] [Full Text] [Related]

  • 19. The use of agomelatine in OCD: effects on the motivational aspects and dysregulated circadian rhythms.
    Perugi G, Quaranta G, Bucci N.
    Expert Opin Investig Drugs; 2015 May 13; 24(5):705-13. PubMed ID: 25727766
    [Abstract] [Full Text] [Related]

  • 20. Melatonin in mood disorders.
    Srinivasan V, Smits M, Spence W, Lowe AD, Kayumov L, Pandi-Perumal SR, Parry B, Cardinali DP.
    World J Biol Psychiatry; 2006 May 13; 7(3):138-51. PubMed ID: 16861139
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.